JP2021530560A5 - - Google Patents

Info

Publication number
JP2021530560A5
JP2021530560A5 JP2021521945A JP2021521945A JP2021530560A5 JP 2021530560 A5 JP2021530560 A5 JP 2021530560A5 JP 2021521945 A JP2021521945 A JP 2021521945A JP 2021521945 A JP2021521945 A JP 2021521945A JP 2021530560 A5 JP2021530560 A5 JP 2021530560A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
group
compound according
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021521945A
Other languages
English (en)
Japanese (ja)
Other versions
JP7348705B2 (ja
JP2021530560A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040690 external-priority patent/WO2020010309A1/en
Publication of JP2021530560A publication Critical patent/JP2021530560A/ja
Publication of JP2021530560A5 publication Critical patent/JP2021530560A5/ja
Application granted granted Critical
Publication of JP7348705B2 publication Critical patent/JP7348705B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021521945A 2018-07-06 2019-07-05 トリアゾールグリコール酸オキシダーゼ阻害剤 Active JP7348705B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862694918P 2018-07-06 2018-07-06
US62/694,918 2018-07-06
US201962827573P 2019-04-01 2019-04-01
US62/827,573 2019-04-01
PCT/US2019/040690 WO2020010309A1 (en) 2018-07-06 2019-07-05 Triazole glycolate oxidase inhibitors

Publications (3)

Publication Number Publication Date
JP2021530560A JP2021530560A (ja) 2021-11-11
JP2021530560A5 true JP2021530560A5 (cg-RX-API-DMAC7.html) 2022-07-13
JP7348705B2 JP7348705B2 (ja) 2023-09-21

Family

ID=67441692

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021521945A Active JP7348705B2 (ja) 2018-07-06 2019-07-05 トリアゾールグリコール酸オキシダーゼ阻害剤

Country Status (14)

Country Link
US (2) US11401246B2 (cg-RX-API-DMAC7.html)
EP (1) EP3817816A1 (cg-RX-API-DMAC7.html)
JP (1) JP7348705B2 (cg-RX-API-DMAC7.html)
KR (1) KR102865323B1 (cg-RX-API-DMAC7.html)
CN (1) CN112399873B (cg-RX-API-DMAC7.html)
AU (1) AU2019297523B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021000050A2 (cg-RX-API-DMAC7.html)
CO (1) CO2021001277A2 (cg-RX-API-DMAC7.html)
IL (1) IL279952B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021000051A (cg-RX-API-DMAC7.html)
PE (1) PE20210859A1 (cg-RX-API-DMAC7.html)
SA (1) SA521420951B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202012930RA (cg-RX-API-DMAC7.html)
WO (1) WO2020010309A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL279952B2 (en) 2018-07-06 2024-11-01 Cantero Therapeutics Inc Triazole glycolate oxidase inhibitors
WO2021086874A1 (en) 2019-11-01 2021-05-06 GyanRx Sciences, Inc. Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
WO2021142155A1 (en) * 2020-01-08 2021-07-15 Orfan Biotech Inc. Processes for preparing triazole glycolate oxidase inhibitors
WO2022066933A1 (en) * 2020-09-24 2022-03-31 Chinook Therapeutics Canada, Inc. Pentafluoro-sulfanyl -substituted triazolyl compounds and methods of use thereof
TW202339727A (zh) * 2021-10-11 2023-10-16 美商坎特羅治療股份有限公司 使用1h-1,2,3-三唑-4-羧酸之治療方法
WO2024109917A1 (zh) * 2022-11-25 2024-05-30 西藏海思科制药有限公司 一种三唑衍生物及其在医药上的应用
WO2024212137A1 (en) * 2023-04-12 2024-10-17 Cantero Therapeutics, Inc. Crystalline forms of a 1h-1, 2, 3-triazole-4-carboxylic acid compound

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0774218B2 (ja) * 1987-03-02 1995-08-09 第一製薬株式会社 ベンゾピラノトリアゾ−ル誘導体
US6187326B1 (en) 1998-12-29 2001-02-13 Thomas T. Yamashita Soil amendment composition
US7022702B2 (en) 2000-04-07 2006-04-04 Qlt Inc. Antiproliferative 1,2,3-thiadiazole compounds
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Mek의 헤테로시클릭 억제제 및 그의 사용 방법
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
CN101307307A (zh) * 2008-07-11 2008-11-19 华东理工大学 一种乙醇酸氧化酶制剂、制备方法及应用
KR20140108594A (ko) 2012-01-10 2014-09-11 에프. 호프만-라 로슈 아게 피리다진 아미드 화합물 및 syk 저해제로서의 이의 용도
JP5455279B1 (ja) 2012-10-25 2014-03-26 アサヒグループホールディングス株式会社 ラテックスの増産方法
TW201437200A (zh) 2013-01-15 2014-10-01 Intermune Inc 溶血磷脂酸受體拮抗劑
US9392796B2 (en) 2013-03-15 2016-07-19 Spogen Biotech Inc. Plant growth-promoting bacteria and methods of use
FR3021843B1 (fr) 2014-06-06 2016-07-08 Lesaffre & Cie Methode et composition pour ameliorer la productivite de plantes non legumineuses
JP5866035B1 (ja) 2015-01-08 2016-02-17 アサヒグループホールディングス株式会社 有効分げつ促進方法
US10766829B2 (en) 2015-03-19 2020-09-08 KOHJIN Life Sciences Co., Ltd. Yeast extract having effect of promoting growth of plant and elongation of root and effect of improving added values of plant
EP3386949A4 (en) * 2015-12-07 2019-11-20 Wake Forest University Health Sciences GLYCOLATE OXIDASE INHIBITORS AND METHOD FOR USE FOR THE TREATMENT OF NIERSTEIN
BR112020013073A2 (pt) * 2017-12-29 2020-12-01 Biomarin Pharmaceutical Inc. composto, composto, estereoisômero único ou mistura de estereoisômeros ou sal farmaceuticamente aceitável, composição farmacêutica, método de tratamento de uma doença ou distúrbio e composto ou sal farmaceuticamente aceitável do mesmo
WO2019133813A1 (en) 2017-12-29 2019-07-04 Orfan Biotech Inc. Glycolate oxidase inhibitors and use thereof
WO2019165159A1 (en) 2018-02-23 2019-08-29 Oxalurx, Inc. Compounds and methods for treating oxalate-related diseases
IL279952B2 (en) 2018-07-06 2024-11-01 Cantero Therapeutics Inc Triazole glycolate oxidase inhibitors
EP3986863A4 (en) 2019-06-19 2023-01-18 BioMarin Pharmaceutical Inc. GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASES

Similar Documents

Publication Publication Date Title
AU2019302534B2 (en) Pyridazine compounds for inhibiting NaV1.8
DE69122084T2 (de) 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
JP2020530487A5 (cg-RX-API-DMAC7.html)
JP2024543512A5 (cg-RX-API-DMAC7.html)
JP2021513534A5 (cg-RX-API-DMAC7.html)
JP2009534358A5 (cg-RX-API-DMAC7.html)
JP2022544714A5 (cg-RX-API-DMAC7.html)
JP2016510323A5 (cg-RX-API-DMAC7.html)
JP2006511587A5 (cg-RX-API-DMAC7.html)
JP2024529527A5 (cg-RX-API-DMAC7.html)
JP2007502295A5 (cg-RX-API-DMAC7.html)
JP2014515349A5 (cg-RX-API-DMAC7.html)
JP2012526728A5 (cg-RX-API-DMAC7.html)
JP2020527175A5 (cg-RX-API-DMAC7.html)
JP2013504593A5 (cg-RX-API-DMAC7.html)
RU2011121876A (ru) Пиразолопиримидиновые соединения-ингибиторы jak и способы
JP2019510082A5 (cg-RX-API-DMAC7.html)
JP2017506666A5 (cg-RX-API-DMAC7.html)
RU2015120478A (ru) Пери-карбинолы
RU2007101236A (ru) Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
JP2019528259A5 (cg-RX-API-DMAC7.html)
RU2016120763A (ru) Ингибиторы респираторного синцитиального вируса
JP2016503403A5 (cg-RX-API-DMAC7.html)
MA40480B1 (fr) Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie
JP2024502473A5 (cg-RX-API-DMAC7.html)